CTOs on the Move

ImmPACT Bio USA

www.immpact-bio.com

 
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Sylvain Roy
Chief Technology Officer Profile

Funding

ImmPACT Bio USA raised $18M on 08/18/2020

Similar Companies

Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

Rani Therapeutics

Rani Therapeutics has developed the RaniPill™, a platform technology for the oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs that today can only be injected. These injections are painful and inconvenient and often affect both patient compliance and quality of life. The pharma industry has been searching for decades to convert injectables into pills, and we believe the solution is the RaniPill™ capsule. We have demonstrated bioavailability similar to subcutaneous injections in both preclinical and clinical studies. Rani has an internal pipeline of molecules, and active collaborations with Novartis and Takeda. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur, and investor.

Steven Rosenstein Associates

Steven Rosenstein Associates is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regeneron

Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we`re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health. So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts.

Kereos Inc

Kereos Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.